Carly Whyte (@CarlyEWhyte) profile picture

Australian immunologist fascinated by the immune processes underlying cancer and allergy | @CCB_Research | Passe & Williams Foundation Fellow

Adelaide, South Australia
Joined August 2019
Photo by Carly Whyte (@CarlyEWhyte)Photo by Carly Whyte (@CarlyEWhyte)Photo by Carly Whyte (@CarlyEWhyte)
Delighted to have the work from my post doc with @LabListon out in @JExpMed today! We show how the cellular context in which IL2 is expressed leads to vastly different outcomes: https://nitter.cf/t.co/isnFdoNczL
6
7
66
Thrilled to share new work led by @JieYang437 in the lab published today in @Nature. We find that Aspirin prevents metastasis by releasing T cells from immune suppression by platelet TXA2. @Cambridge_Uni @CRUKCamCentre rdcu.be/eci1U
29
216
24
712
142,235
We are excited to recruit a PhD student for 2025 @CCB_Research in Adelaide to tackle immune dysfunction in head and neck cancer. Please share and apply: unisa.edu.au/research/degree…
1
2
1
5
1,064
Following several kind requests, here is a high-level summary of our pre-print in @biorxivpreprint (doi: doi.org/10.1101/2024.10.03.6…): STAMP: Single-Cell Transcriptomics Analysis and Multimodal Profiling through Imaging STAMP is a scalable, cost-efficient method for single-cell transcriptomics and multimodal profiling through imaging. It bypasses sequencing, significantly reducing costs while enhancing throughput. #SingleCellRNA #SpatialOmics #STAMP The motivation for this paper comes from the limitations of current scRNA-seq methods, which are costly, inefficient, and struggle to capture low- and high-abundance transcripts. Challenges like droplet instability, cell damage, limited cell capture, cross-contamination, inefficient indexing, and high sequencing costs affect ultra-low and ultra-high cell profiling, hindering accurate analysis of complex cell populations. #Limitations #DropletMicrofluidics STAMP addresses these issues with a scalable, cost-effective, sequencing(costs)-free approach that works efficiently across ultra-low to ultra-high cell numbers, while preserving cellular morphology and enabling multimodal profiling. #SpatialOmics #UltraLow #UltraHigh STAMP uses an imaging-based approach to perform high-throughput RNA and protein profiling by stamping cells onto slides compatible with CosMx and Xenium platforms, allowing multimodal profiling in a single run. #Proteomics STAMP supports single-modal (RNA/protein) and multimodal (RNA + protein) profiling, enhancing experimental flexibility and scalability. This versatility is essential for large-scale atlases and mixed-sample experiments. #SingleCellAtlas #MultiSampleProfiling STAMP scales easily: from less than 100 to millions of cells. It overcomes limitations in droplet-based systems, where throughput is often constrained by sequencing costs. #HighThroughput STAMP handles diverse sample types: PBMCs, dissociated tumors, nuclei, and stem cells. It also excels with fragile or archived tissues, where traditional methods often fail to yield high-quality data. #ArchivedSamples STAMP eliminates sequencing costs, making large-scale single-cell analysis accessible to more labs. #CostEfficiency Here’s a cost comparison between GEM-X and STAMP-X for RNA profiling: GEM-X RNA (20k cells): $0.0764/cell 1M cells = $76,400 (cost/cell = $0.0764) 2M cells = $152.800 (cost/cell = $0.0764) 3M cells = $229,200 (cost/cell = $0.0764) STAMP-X RNA (1M cells): $0.0075/cell 1M cells = $7,500 (cost/cell = $0.0075) 2M cells = $7,500 (cost/cell = $0.00375) 3M cells = $7,500 (cost/cell = $0.0025) In STAMP cells remain intact after imaging, enabling further downstream applications like histological validation or additional molecular assays, adding value to each sample. #NonDestructiveAnalysis We tested STAMP’s sensitivity by identifying, ultra-rare, circulating tumor cells (CTCs) spiked into PBMCs at 1:100,000. Such sensitivity is essential for clinical diagnostics, particularly in rare cell detection. #CTCs #CancerDiagnostics In a high-throughput immuno-phenotyping experiment, STAMP profiled 1.7M PBMCs, capturing a median of 83 transcripts and 49 genes per cell. This resulted in high-resolution immune profiling. #Immunology #HighThroughputProfiling 31 immune cell states were mapped in PBMCs, capturing rare subpopulations (Th1/Th2/Th17 and NK subtypes). Detailed immune phenotyping is critical for understanding immune diversity in health and disease. #ImmuneMapping Whole cells vs. nuclei: STAMP's ability to profile both whole cells and nuclei is crucial for samples with low RNA content (e.g., archived tissues), increasing the platform’s applicability. #NucleiProfiling #SingleCellOmics STAMP integrates RNA and protein profiling. In cancer cell line profiling, RNA and protein data showed strong correlations, confirming the platform’s robustness in multimodal data collection. #MultimodalProfiling STAMP’s multimodal profiling produced high-resolution immune maps, combining RNA and protein data. This approach is essential for dissecting complex immune states and understanding functional responses. STAMP excels in low-input samples. We demonstrated its ability to accurately profile as few as 100 cells, which is critical for studying rare populations in small samples. #LowInput #RareCell In a BMP4-driven stem cell differentiation model, STAMP captured dynamic changes from pluripotency to mesoderm and endoderm progenitors over multiple timepoints, tracking lineage differentiation. #StemCellDifferentiation #LineageTracing Trajectory analysis shows that STAMP’s resolution makes it a powerful tool for developmental biology and perturbation studies. #DevelopmentalBiology #hESC STAMP allows multi-sample profiling on a single slide, reducing batch effects and improving comparative analysis, particularly in drug response and perturbation studies. #MultiSampleAnalysis #PerturbationScreening STAMP represents a significant advance in single-cell research, offering scalable, multimodal RNA/protein profiling at low cost. Its versatility will support a broad range of research, from basic to clinical. #SingleCellTechnology Lots more coming soon... @DrJasPlummer @hoheyn @pascual_reguant @EmanuelePitino1 @helucro @ximbaozao @irepan_salvador @Kellieiswise @m_mohenska @jc_nietos @cnag_eu @StJudeResearch @ACEpigenetics @M_ayco_N @eliseinsing Bill Flynn, Yutian Liu, Hannah Chasteen
6
39
3
153
22,450
Here we go…repurposing spatial imaging techs to achieve ultra-low to ultra-high, multiplexing, nuclei, cells, single (RNA or Protein), multimodal (RNA and Protein), super cheap! NO SEQUENCING! @10xGenomics @nanostringtech @AkoyaBio @bruker
7
39
3
99
21,336
Carly Whyte retweeted
We are recruiting! Come join us in Adelaide to work on cutting-edge translational research and contribute to developing CAR-T cell therapies for brain tumours. Two post-doc positions available, closing soon, details at careers.pageuppeople.com/532…
6
11
703
Congrats to the team @LabListon @jldvib @olivertburton on this wonderful study 👏 #TissueTregs surprising us on every turn!
Biggest paper yet from the lab out now in @ImmunityCP! It is a massive #openscience resource on #tissueTregs, and what makes #Tregs tick in the #tissues. Spoiler-alert: Tissue Tregs are really different from what we all thought. 🧵 1/21 sciencedirect.com/science/ar…
1
7
1,580
So great to have this preprint out in the world. My first paper in this new field I love, #StrepA. Thanks to @JoshOsowicki and Andrew Steer @MCRI_for_kids for providing such a cool Strep A challenge model to study, & to all our coauthors, particularly @hrcfrost & @njmoreland
Excited to share this #StrepA human challenge preprint from a 🌟 team. @hrcfrost @DrDanikaHill @njmoreland @RHCMcG @AlanaWhitcombe @LicciardiLab @jcarapetis et al. Before/after serum IgG & saliva IgA for 19 #StrepA antigens & more 😊 biorxiv.org/content/10.1101/…
1
6
39
3,143
Very excited (& nervous) to share what we've been working on the past many years. Only took 3 first authors (Schreuder the experimentalist, @DawnSLin the analyst, and @syzmath the modeller) & co-senior Weber (computational, modeller, SynBio extraordinaire) biorxiv.org/content/10.1101/…
This represents how we believe haematopoiesis is actually proceeding at a clonal level. I'll walk through our preprint early next week. "A multi-track landscape of haematopoiesis informed by cellular barcoding and agent-based modelling" biorxiv.org/content/10.1101/…
4
55
2
208
50,712
Carly Whyte retweeted
Resource: A mega-thread of various #academic #career development projects I have worked on over the years. First up, building career options into your PhD studies, written as part of #ImmunologyFutures for @ImmunolCellBiol with @lydiamakaroff nitter.cf/LabListon/status/16791…
2
22
6
80
39,791
Carly Whyte retweeted
Flow/CyTOF users and leaders: here is an interface that allows you to see exactly where a given cell on a biaxial plot is on a corresponding UMAP. More details:
7
40
2
229
41,903
Seeking experienced senior molecular biologist to lead all single cell/spatial applications running in my lab. Must be willing to learn new stuff all the time & teach students! —>Postdoc Level A or B based on experience. Email CV & Refs to [email protected]
2
38
3
68
25,483
Immuno-PhD/Masters/Honours students, it can be hard to decide career direction. Register for our translational immunology conference (14-17 May, Melbourne) & hear from these huge companies! It could decide the next phase of your scientific career! apvic.org/
2
5
791
We hope this protocol will be a useful addition to your flow toolkit - better staining, less antibody, and shorter nights in the lab! We also provide some advice on fixatives, titration, buffer choice and optimising the perfect staining conditions 👌
For anyone doing #flowcytometry, would you like to have a new protocol that reduces your #antibody costs by ~10-fold and also gives you higher quality data, with better signal-to-noise ratio? Yes? Then read work by @olivertburton and @CarlyEWhyte. 1/6 currentprotocols.onlinelibra…
5
11
64
Thank you to everyone who came to our publishing panel and specially our panelists @tahliajperry @kariisssaaa @CarlyEWhyte and Dr Cameron Bastow. We had an amazing turnout and an insightful discussion on getting your hard work published. Happy publishing everyone! 📖 📈🤩
1
3
1
17
Carly keeping our youngest ever Session Chair happy 👏 #AIR17 #immunology #AcademicTwitter @hosp_research @ASImmunology
1
4
23
This is absolutely wild - nature (as in mother) never ceases to amaze nature.com/articles/s41556-0…
7
166
23
739
Interested in tumour immunology? @Gotot_Lab @Unibonn and I are looking for 2 PhD students @BonnMelbPhD to work on Tregs in tumour. Students will spend their time between @UniBonn and @ONJCRI @UniMelbMDHS. Please RT @ASImmunology @dgfi_org @ImmunoSens
2
24
2
42
Carly Whyte retweeted
About 50-60% of advanced melanoma patients do not respond to immunotherapy. Why and what can we do about it? In this preprint we describe a prospective longitudinal clinical study we designed/conducted to address this (1/9). biorxiv.org/cgi/content/shor…
5
28
9
155
We've got positions open! #Postdoc #job in #neuroimmunology. Welcoming applicants from #neuroscience, #immunology, #molecularbiology. Come join an international, diverse, LGBT+ friendly team to work on an exciting @wellcometrust project! babrahaminstitute.livevacanc…
60
4
100